Glutamic acid decarboxylase antibodies in non-insulin-dependent diabetes patients with secondary sulfonylurea failure in Thailand

The objective of this study was to determine the frequency of glutamic acid decarboxylase antibody (GAD-Ab) in Thai non-insulin-dependent diabetes (NIDDM) patients who had secondary sulfonylurea failure. Sera were collected from 40 NIDDM patients, who had history of secondary failure to treatment wi...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 1997-09, Vol.37 (3), p.193-197
Main Authors: Rattarasarn, Chatchalit, Aguilar Diosdado, Manuel, Soonthornpun, Supamai
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies - blood
Biological and medical sciences
C-Peptide - blood
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - immunology
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
Glutamate Decarboxylase - blood
Glutamate Decarboxylase - immunology
Glutamic acid decarboxylase antibodies
Humans
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Insulin-dependent diabetes
Male
Medical sciences
Middle Aged
Non-insulin-dependent diabetes
Sulfonylurea Compounds - adverse effects
Sulfonylurea Compounds - therapeutic use
Thailand
Treatment Failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to determine the frequency of glutamic acid decarboxylase antibody (GAD-Ab) in Thai non-insulin-dependent diabetes (NIDDM) patients who had secondary sulfonylurea failure. Sera were collected from 40 NIDDM patients, who had history of secondary failure to treatment with sulfonylurea, for analysis of fasting c-peptide and GAD-Ab. Both c-peptide and GAD-Ab were measured using radioimmunoassay method. Of 40 patients, ten (25.0%) were positive for GAD-Ab with a mean level of 59.9 U/ml (median 58.5, range 3.4–127). Patients with GAD-Ab(+) had a significantly lower fasting c-peptide levels than those with GAD-Ab(−) albeit shorter duration of diabetes (0.21±0.19 (S.D.) versus 0.52±0.33 nmol/l; P=0.003). Duration of treatment with sulfonylurea in patients with GAD-Ab(+) was also shorter (4.6±3.5 versus 10.4±5.5 years; P=0.001). Age at onset of diabetes did not differ between these two groups. Among 40% of patients who had insulin deficiency (fasting c-peptide level
ISSN:0168-8227
1872-8227
DOI:10.1016/S0168-8227(97)00070-3